Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Ghent
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
\> 18 years old
PCa, treated with curative intent (radical prostatectomy, primary radiotherapy, or a combination of both) and oligorecurrent/oligopersistent metastasis (1 - 5 lesions) on imaging (PSMA-PET, CT, MRI).
Recurrence or progression of metastases on imaging (PSMA-PET, CT, MRI) that cannot be treated with SBRT, either due to a history of previous high-dose radiotherapy with dose constraints, because SBRT is technically unfeasible or unsafe for the specific lesions, or because the patient refuses to undergo SBRT.
PSMA-positive lesion
Lesions up to 4 cm that are suitable and safe for TA with an anticipated high rate of technical success
'Eastern Cooperative Oncology Group' (ECOG) performance status of 2 or less.
Patients can be androgen sensitive (mHSPC) or castration resistant (mCRPC).
All patients will be discussed at the Multidisciplinary Tumor Board.
You may not be if
\<18y
Severe comorbidity which limits the further life expectancy of the patient to \< 2 years (opinion of the physician) and no malignancies \< 2 years ago except for non-melanoma skin cancer and non-muscle invasive bladder cancer.
No local radical treatment of the primary tumor was performed.
Lack of compliance
Absence of consent of the patient
Location: intracranial
Clareo Health | Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)
